维普期刊资源整合服务平台（V6.5）

24篇 您的检索式：作者名="Kenakin"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Recent progress in discovery of small-molecule CCR5 ehemokine receptor ligands as HIV-1 inhibitors显示文摘	Kazmierski W Bfulco N Kenakin T	2003	Bioorg Med Chem2003，11，13：	1
2	Seven transmembrane receptors as shapeshifting proteins:the impact of allosteric modulation and functional selectivity on new drug discovery显示文摘	Kenakin T Miller LJ	2010	Pharmacol Rev2010，62，2：	1
3	Determining the potency and molecular mechanism of action of insurmountable antagonists 显示文摘	Kenakin T Jenkinson S Watson C	2006	J Pharmaeol Exp Ther2006，319，2：	1
4	G protein-coupled receptor allosterism and eomplexing显示文摘	Christopoulos A Kenakin T	2002	Pharmacol Rev2002，54，2：	1
5	Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery 显示文摘	KENAKIN T MILLER LJ	2010	Pharmacol Rev2010，62，2：	1
6	Collateral efficacy in drug discovery: taking advan- tage of the good (anosteric) nature of 7TM receptors显示文摘	KENAKIN T	2007	Trends Pharmacol Sci2007，28，8：	1
7	Efficacy as a vector: the relative prevalence and paucity of inverse agonism显示文摘	Kenakin T	2004	Mol Pharmacol2004，65，1：	1
8	Biased signalling and allosteric machines : new vistas and challenges for drug discovery 显示文摘	Kenakin TP	2012	Br J Pharmacol2012，165，6：	1
9	Seven transmembrane receptors as shapeshihing proteins: the impact of allosteric modulation and functional selectivity on new drug discovery显示文摘	Kenakin T and Miller L J	2010	Pharma col Rev2010，62，2：	1
10	Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and func- tional selectivity on new drug discovery显示文摘	KENAKIN T MILLER L J	2010	Pharmacol Rev2010，62，：	1
11	Functional, selectivity and biased receptor signaling显示文摘	Kenakin T	2011	J Pharmacol Exp Ther2011，336，2：	1
12	G-protein coupled receptors as allosteric machines显示文摘	Kenakin T	2004	Receptors Channels2004，10，2：	1
13	The CCR5 receptor- based mechanism of action of 873140, a potent allos- teric noncompetitive HIV entry inhibitor显示文摘	Watson C Jenkinson S Kazmierski W Kenakin T	2005	Mol Pharmacol2005，67，：	1
14	Predicting therapeutic value in the lead optimization phase of drug discovery 显示文摘	Kenakin T	2003	Nat Rev Drug Discov2003，2，6：	1
15	G protein-coupled receptor allosterism and complexing显示文摘	Christopoulos A Kenakin T	2002	Phannacol Rev2002，54，2：	1
16	Efficacy as a vector:The relative prevalence and paucity of inverse agonism显示文摘	KENAKIN T	2004	Mol Pharmacol2004，65，1：	1
17	The classification of seven transmembrance receptors in recombinant expression systems 显示文摘	Kenakin T	1996	Pharmacol Rev1996，48，3：	1
18	The classification of seven transmembrane receptors in recombinant expression systems显示文摘		1996	Pharmacol Rev1996，48，3：	1
19	Predicting therapeutic value in the lead optimization phase of drug discovery显示文摘	Kenakin T	2003	Rev Drug Discov2003，2，6：	1
20	Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40:identification of agonist and antagonist small molecules显示文摘	Briscoe CP Peat AJ McKeown SC Corbett DF Goetz AS Littleton TR McCoy DC Kenakin TP Andrews JL Ammala C Fornwald JA Ignar DM Jenkinson S		0，，05：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示